What do systematic reviews say?

Gene therapy vs no gene therapy control

Gene therapy showed no clear difference in amputation‐free survival compared with no gene therapy control (moderate certainty).

• Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
  OR 1.68 [0.75, 3.76]
  4 studies · 756 participants
  Moderate

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.85 [0.68, 1.08]
  8 studies · 940 participants
  Moderate

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI may leads to lower progression‐free survival (PFS) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.55, 0.89]
  8 studies · 940 participants
  Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.73 [0.61, 0.86]
  5 studies · 778 participants
  High

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.49 [0.15, 1.64]
  1 study · 150 participants
  Very low

Bevacizumab plus chemotherapy vs chemotherapy alone

Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.49 [0.42, 0.58]
  5 studies · 778 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.86 [0.67, 1.11]
  1 study · 282 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.8, 1.06]
  3 studies · 1250 participants
  Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.99 [0.84, 1.17]
  2 studies · 1451 participants
  Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.97 [0.88, 1.07]
  2 studies · 2776 participants
  Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.9 [0.79, 1.02]
  3 studies · 1564 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.99 [0.79, 1.25]
  1 study · 1015 participants
  Moderate

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.56 [0.44, 0.72]
  1 study · 282 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) leads to lower progression‐free survival (PFS) compared with chemotherapy alone (high certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.73 [0.65, 0.82]
  3 studies · 1250 participants
  High

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.88 [0.77, 1]
  2 studies · 1451 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Moderate

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1132 participants
  Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.82 [0.64, 1.05]
  2 studies · 2746 participants
  Very low